“In the phase 3 POLO trial, maintenance olaparib provided a statistically significant and clinically meaningful improvement in progression-free survival (PFS), versus placebo, in patients with a germline BRCA1 and/or BRCA2 mutation whose disease had not progressed during first-line platinum-based chemotherapy,” wrote Hedy Kindler, MD, and co-investigators. Read more . . .
Results of additional analyses of elderly patients in the phase 3 POLO trial showed the safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer to be consistent regardless of age, according to data presented at the virtual 22nd ESMO World Congress on Gastrointestinal Cancer.